Index Vol. 49 No. 4

A

Ablated PrP genes, transgenic mice with, 898-899
AD *see* Alzheimer's disease
AGUET M *see* WEISSMANN C
AGUZZI A *see* WEISSMANN C
Alzheimer's disease (AD), 768-770, 874, 920, 925-926 (*ubiquitous*)
  neuropathology, comparison with scrapie, 805
  PrP accumulation, and, 860-872, 869
Amyloid plaques, neuropathology, 797-798
Amyloid-enhancing factor, 924-925
Amyloidogenesis, 923-924
Amyloidoses and PrP accumulation, 860-872, 869
AUTILIO-GAMBETTI L *see* GAMBETTI P

B

BELL JE & IRONSIDE JW: Neuropathology of spongiform encephalopathies in humans, 738-777
Bovine spongiform encephalopathy (BSE), epidemiology and control of, 932-969
BRADLEY R & WILESMITH JW: Epidemiology and control of bovine spongiform encephalopathy (BSE), 932-959
Brefeldin A, inhibition of PrP^{Sc} synthesis, 899-901
BRUCE ME: Scrapie strain variation and mutation, 822-838
BöELER *see* WEISSMANN C

C

CAUGHEY B: Scrapie-associated PrP accumulation and its prevention: insights from cell culture, 860-872
Cell biology and transgenetics (Tg) of prion diseases: investigations of PrPSc synthesis and diversity, 873-912
Cell culture in the investigation of scrapie, 860-872
Chimeric Mo/SHa PrP genes, propagation of artificial prions in transgenic mice, 888-898
Classification of SEs, 740-742
Clinicopathological correlations, 763-768
Configurational changes in amyloidogenesis, 923-924
Conformational transitions in prion synthesis, 904-906
Congo red inhibition of protease-resistant PrP accumulation, 864-869
CORTELLI P *see* GAMBETTI P
Creutzfeldt-Jakob disease (CJD), 919 (*ubiquitous*)
  BSE and, 967-968
  epidemiology of, 960-970
  genetic marker for wandering Jews of the Diaspora, 919
  history, 738-740
  pathology of, 744-754
  point mutation for large Finnish pedigree of familial
  risk factors for, 962-966
  scrapie agents, properties of, and, 728-729
  syndromes, genetic control of generation of infectious amyloids, 914-917

D

DeARMOND SJ: Overview of the transmissible spongiform encephalopathies: Prion protein disorders, 725-737
Dementia of the frontal lobe type, 768-770
Developments in diagnosis for prion diseases: TATEISHI J & KITAMOTO T, 971-979
Diagnosis (differential) of human SEs, 768-771
Diagnosis for prion diseases, developments in, 971-979
Diagnostic criteria for human SEs, 741
Differential diagnosis of human SEs, 768-771

Index Vol. 49 No. 4

A

Ablated PrP genes, transgenic mice with, 898-899
AD *see* Alzheimer's disease
AGUET M *see* WEISSMANN C
AGUZZI A *see* WEISSMANN C
Alzheimer's disease (AD), 768-770, 874, 920, 925-926 (*ubiquitous*)
  neuropathology, comparison with scrapie, 805
  PrP accumulation, and, 860-872, 869
Amyloid plaques, neuropathology, 797-798
Amyloid-enhancing factor, 924-925
Amyloidogenesis, 923-924
Amyloidoses and PrP accumulation, 860-872, 869
AUTILIO-GAMBETTI L *see* GAMBETTI P

B

BELL JE & IRONSIDE JW: Neuropathology of spongiform encephalopathies in humans, 738-777
Bovine spongiform encephalopathy (BSE), epidemiology and control of, 932-969
BRADLEY R & WILESMITH JW: Epidemiology and control of bovine spongiform encephalopathy (BSE), 932-959
Brefeldin A, inhibition of PrP^{Sc} synthesis, 899-901
BRUCE ME: Scrapie strain variation and mutation, 822-838
BöELER *see* WEISSMANN C

C

CAUGHEY B: Scrapie-associated PrP accumulation and its prevention: insights from cell culture, 860-872
Cell biology and transgenetics (Tg) of prion diseases: investigations of PrPSc synthesis and diversity, 873-912
Cell culture in the investigation of scrapie, 860-872
Chimeric Mo/SHa PrP genes, propagation of artificial prions in transgenic mice, 888-898
Classification of SEs, 740-742
Clinicopathological correlations, 763-768
Configurational changes in amyloidogenesis, 923-924
Conformational transitions in prion synthesis, 904-906
Congo red inhibition of protease-resistant PrP accumulation, 864-869
CORTELLI P *see* GAMBETTI P
Creutzfeldt-Jakob disease (CJD), 919 (*ubiquitous*)
  BSE and, 967-968
  epidemiology of, 960-970
  genetic marker for wandering Jews of the Diaspora, 919
  history, 738-740
  pathology of, 744-754
  point mutation for large Finnish pedigree of familial
  risk factors for, 962-966
  scrapie agents, properties of, and, 728-729
  syndromes, genetic control of generation of infectious amyloids, 914-917

D

DeARMOND SJ: Overview of the transmissible spongiform encephalopathies: Prion protein disorders, 725-737
Dementia of the frontal lobe type, 768-770
Developments in diagnosis for prion diseases: TATEISHI J & KITAMOTO T, 971-979
Diagnosis (differential) of human SEs, 768-771
Diagnosis for prion diseases, developments in, 971-979
Diagnostic criteria for human SEs, 741
Differential diagnosis of human SEs, 768-771

Diversity in the neuropathology of scrapie-like diseases in animals: FRASER H, 792-809

E

Epidemiology and control of bovine spongiform encephalopathy (BSE): BRADLEY R & WILESMITH JW, 932-959
Epidemiology of Creutzfeldt-Jakob disease: WILL RG, 960-970

F

Familial amyloidotic polyneuropathy (FAP), transthyretin amyloidoses of, 920-923
Familial and gene mutation cases: clinicopathological correlations, 766
Familial fatal insomnia (FFI), 919, 920
Fatal familial insomnia and the widening spectrum of prion diseases: GAMBETTI P, PETERSEN R, MONARI L, TABATON M, AUTILIO-GAMBETTI L, CORTELLI P, MONTAGNA P, LUGARESI E, 980-994
Finnish pedigree of familial CJD, CJD point mutation, 919
FISCHER M *see* WEISSMANN C
FRASER H: Diversity in the neuropathology of scrapie-like diseases in animals, 792-809

G

GAJDUSEK DC: Genetic control of nucleation and polymerization of host precursors to infectious amyloids in the transmissible amyloidoses of brain, 913-931
GAMBETTI P, PETERSEN R, MONARI L, TABATON M, AUTILIO-GAMBETTI L, CORTELLI P, MONTAGNA P, LUGARESI E: Fatal familial insomnia and the widening spectrum of prion diseases, 980-994
Genetic control of nucleation and polymerization of host precursors to infectious amyloids in the transmissible amyloidoses of brain: GAJDUSEK DC, 913-931
Gerstmann-StrÑussler-Scheinker (GSS) disease/syndrome, (*ubiquitous*)
  history, 739-740
  pathology of, 754-755
  MoPrP genes, transgenic mice expressing, 882-888
GOLDMANN W: PrP gene and its association with spongiform encephalopathies, 839-859

H

Historical aspects of human SEs, 738-740
Human neuropathology of SEs, 738-777
Huntington's disease, 768-770

I

Iatrogenic cases: clinicopathological correlations, 766-768
Immunoblotting, 972
Immunohistochemistry, 972-974
Immunolabelling the PrP protein, pathology revealed by, 799-801
Immunostaining of PrP, 755-763
Inactivation of SE agents: TAYLOR DM, 810-821
Indiana kindred, 977
Inherited prion disease,
  murine model of, 887-888
  subtypes, 986-989
Inhibition (chemical) of protease-resistant PrP accumulation, 864-869

K

KITAMOTO T *see* TATEISHI J
Kuru (*ubiquitous*)
  history, 738-740
  Oravske, 917-918
  pathology of, 754
  plaques, 913
Laboratory and autopsy handling of human SEs, 742-743
Lewy body disease, diffuse, 768-770
LUGARESI E *see* GAMBETTI P

M

Metabolic encephalopathies, 768-770
Models
  cell culture models of scrapie, 861-862
  murine, of inherited prion disease, 887-888
  of scrapie-like agents, molecular, 835-836
MONARI L *see* GAMBETTI P
MONTAGNA P *see* GAMBETTI P
MoPrP-B genes, transgenic mice expressing, 879-882

N

Neuroanatomical projection pathways in scrapie pathology and neurogenesis, 798-799
Neuropathology of
  prion isolates in Syrian hamsters, contrasting, 894-895
  scrapie-like diseases in animals, diversity of, 792-809
  spongiform encephalopathies in humans: BELL JE, IRONSIDE JW, 738-777
Non-familial forms of SE, 989-990

O

Open reading frame (ORF) of the PrP gene, 842-843
Oravske kuru, 917-918
ORF-EXON of PrP gene, 842-843
Overview of the transmissible spongiform encephalopathies: Prion protein disorders: DeARMOND SJ, 725-737

P

Parkinson's disease, 874
Pathogenesis of scrapie, 778-791
  central, 783-787
  peripheral, 781-783
Pathological classification of human SEs, 741
Pathology of human SEs, 743-755
PETERSEN R *see* GAMBETTI P
Phenotypic expression of different mutations in the CJD amyloid precursor, 920
Pick's disease, 768-770
5PRIME-EXON(S) of PrP gene, 845-848
Prion hypothesis: purification of the scrapie agent, 729-733
PrP gene and its association with spongiform encephalopathies: GOLDMANN W, 839-859
Prion protein (PrP) (*ubiquitous*)
  disorders (transmissible spongiform encephalopathies, TSEs), 725-737
  gene, 839-859
    analysis, 974-978
    promoter, 848-849
  immunostaining, 755-763
  in agent-host interactions, 833-835
  metabolism, 862-864
  role of, in prion diseases, 995-1011
  structure and properties, 849-855
'Protein only' hypothesis, 996, 999
PrP^{Sc} synthesis
  and diversity, investigations of, 873-912
  is a post-translational process, 899-904
PRUSINER SB: Transgenetics and cell biology of prion diseases: investigations of PrP^{Sc} synthesis and diversity, 873-912

R

Role of PrP in prion diseases: WEISSMANN C, BöELER, AGUZZI A, SAILER A, FISCHER M, AGUET M

S

SAFs *see* Scrapie associated fibrils
SAILER A *see* WEISSMANN C
SCOTT JR: Scrapie pathogenesis, 778-791
Scrapie (*ubiquitous*)
  and CJD agents, properties of, 728-729
  agents, purification of, 729-733
  incubation periods and brain pathology, 823-827
  interspecies transmission, 830-832
  isolation of strains in mice, 827
  model, 815-818
  mouse-passaged strains, 827-830
  neuropathology,
    comparison with Alzheimer's disease, 805
    ultrastructure of, 802-804
  pathogenesis: SCOTT JR, 778-791
  strains, 1006
  strain variation and mutation: BRUCE ME, 822-838
  susceptibility in mice devoid of PrPC, 999-1004
Scrapie-associated
  fibrils (SAFs), 730, 802, 913
  PrP accumulation and its prevention: insights from cell culture: CAUGHEY B, 860-872
Scrapie-like
  agents, molecular models, 835-836

diseases
experimental, 795-796
lesion profiles, 796-797
naturally-occurring, 793-795
neuropathology, diversity of, 792-809
(natural), strain variation in, 832-833
Sporadic cases, clinicopathological correlations, 763-766
Spongiform encephalopathies (SE), (*ubiquitous*)
agents, stability, 811-815
inactivation of agents of, 810-821
Sulfated glycan inhibition of protease-resistant PrP accumulation, 865-869
Swedish family study, 977
Syrian hamster (SHa) PrP genes, transgenic mice expressing, 874-879

T

TABATON M *see* GAMBETTI P
TATEISHI J & KITAMOTO T: Developments in diagnosis for prion diseases, 971-979
TAYLOR DM: Inactivation of SE agents, 810-821
Texas red, 973
Therapy for TSEs, possibility of, 869
Transgenetics (Tg) and cell biology of prion diseases: investigations of PrPSc synthesis and diversity: PRUSINER SB, 873-912
Transgenic mice
expressing
chimeric Mo/SHa PrP genes, propagation of artificial prions in, 888-898
Gerstmann-Sträussler-Scheinker syndrome (GSS) MoPrP genes, 882-888
MoPrP-B genes, 879-882
Syrian hamster (SHa) PrP genes, 874-879
with ablated PrP genes, 898-899
Transmissible amyloidoses of brain, genetic control of nucleation and polymerization of host precursors to infectious amyloids in the, 913-931
Transmissible spongiform encephalopathies (TSEs)
characteristics of syndromes, 726-728
prion protein disorders, 725-737
relationship of PrP to, 996-999
Transthyretin amyloidoses of familial amyloidotic polyneuropathy (FAP), 920
TSEs *see* Transmissible spongiform encephalopathies
Tunicamycin, 902

W

WEISSMANN C, BöELER, AGUZZI A, SAILER A, FISCHER M, AGUET M: PrP, role of, in prion diseases, 995-1011
WILESMITH JW *see* BRADLEY R
WILL RG: Epidemiology of Creutzfeldt-Jakob disease, 960-970